Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Epivax Inc.
Headquarters: Providence, RI, United States of America
Website: http://www.epivax.com
Year Founded: 1998
Status: Private
BioCentury | Mar 1, 2025
Management Tracks
Orbus names co-founder, COO Levin president
Plus: Michael Bell becomes CTO of Chemify, and updates from Genbio AI and Epivax
BioCentury | Jun 14, 2022
Product Development
Poxvirus agents, by the mechanisms
The mechanisms of products approved for monkeypox and other orthopoxviruses offer the potential for combinations
BioCentury | Apr 8, 2021
Product Development
Rounding up intranasal COVID-19 vaccines: Data Byte
In the race to develop the next generation of COVID-19 vaccines, at least 22 vaccine programs are being developed with an intranasal route of administration. Intranasal vaccines may provide
BioCentury | Feb 6, 2021
Product Development
Picking vaccine strategies that could hold up to COVID variants
COVID vaccines that induce broad polyclonal responses or potently enlist T cells could upstage single-antigen products when it comes to variants
BioCentury | Jan 29, 2020
Company News
Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more
Items per page:
1 - 10 of 14